These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 578448)

  • 21. [The influence of artefacts on visual evoked respnses (author's transl)].
    Straub W; Baerwald C
    Klin Monbl Augenheilkd; 1977 Jun; 170(6):884-9. PubMed ID: 894994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [High doses of fluphenazine: clinico-therapeutical trials].
    Benassi P; Bertolotti P; De Pietri L
    Riv Sper Freniatr Med Leg Alien Ment; 1968 Dec; 92(6):1803-25. PubMed ID: 4888750
    [No Abstract]   [Full Text] [Related]  

  • 24. [Visual evoked potentials and water deprivation of rats during intrahypothalamic application of substance P].
    Kolle U; Bartsch P
    Biomed Biochim Acta; 1988; 47(12):1065-71. PubMed ID: 2473740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
    Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
    [No Abstract]   [Full Text] [Related]  

  • 26. The schizophrenic. The pill or not the pill--fluphenazine enanthate an answer.
    Brauer WW
    Minn Med; 1972 Nov; 55(11):1058-60. PubMed ID: 4669975
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
    Altamura AC; Mauri MC; Girardi T; Panetta B
    Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroleptic-induced lateral asymmetry of visual evoked potentials in schizophrenia.
    Mintz M; Tomer R; Myslobodsky MS
    Biol Psychiatry; 1982 Jul; 17(7):815-28. PubMed ID: 6126228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment with high doses of fluphenazine hydrochloride].
    Korbar M; Belev B; Pauković M
    Neuropsihijatrija; 1976; 24(1-4):115-9. PubMed ID: 1031196
    [No Abstract]   [Full Text] [Related]  

  • 30. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH; Gelder MG
    Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
    [No Abstract]   [Full Text] [Related]  

  • 31. [States of preadjustment under conditions of prolonged activation according to evoked potential findings in schizophrenic patients].
    Savina TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(12):1848-52. PubMed ID: 602560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
    Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
    J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol.
    Levenson AJ; Burnett GB; Nottingham JD; Sermas CE; Thornby JI
    Curr Ther Res Clin Exp; 1976 Nov; 20(5):695-700. PubMed ID: 825356
    [No Abstract]   [Full Text] [Related]  

  • 34. Dopamine antagonism by thioridazine in schizophrenia.
    Meltzer HY; Sachar EJ; Frantz AG
    Biol Psychiatry; 1975 Feb; 10(1):53-7. PubMed ID: 1120175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Policlinical schizophrenia therapy with longtime neuroleptic agent fluphenazine decanoate].
    Haase HJ; Steuer A; Knaack M
    Med Welt; 1973 Feb; 24(8):306-7. PubMed ID: 4688219
    [No Abstract]   [Full Text] [Related]  

  • 36. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK; Wong KE; Tay WK; Gill RC
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluphenazine decanoate maintenance in schizophrenia: a retrospective study.
    Polonowita A; James NM
    N Z Med J; 1976 May; 83(563):316-8. PubMed ID: 1066554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visual evoked responses in schizophrenics during autogenic training.
    Motoda K; Shibata JI; Inanaga K; Isozaki H
    Am J Clin Hypn; 1969 Oct; 12(2):67-74. PubMed ID: 5351675
    [No Abstract]   [Full Text] [Related]  

  • 40. [Visually evoked potential following the electrically induced seizure in the kindled cats (author's transl)].
    Nakatsuka K; Ono K; Baba H
    Nippon Ganka Gakkai Zasshi; 1980 Oct; 84(10):1634-9. PubMed ID: 7257981
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.